Skip to Main Content

A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia

Conditions

Myeloid and Monocytic Leukemia

Phase I

What is the purpose of this trial?

This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM 003 dose levels when administered to subjects with previously treated relapsed or refractory AML.

Subjects will self-administer oral LAM 003 either once or twice per day as long as they are safely benefitting from therapy. Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels of LAM 003 using a standard 3+3 dose-escalation design. Based on the pattern of dose-limiting toxicities observed in the first 4 weeks of therapy, escalation will proceed to define a recommended LAM-003 dosing regimen.

  • Trial with
    LAM Therapeutics, Inc.
  • Start Date
    03/28/2018
  • End Date
    08/31/2019
Trial Image

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    03/30/2018
  • Study HIC
    #2000022212